Edesa Biotech Receives FDA Clearance For Its Investigational New Drug Application For Its Phase 2 Clinical Trial Of EB06 In Vitiligo
Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported that the U.S. Food and Drug Administration
Edesa got permission to test a new vitiligo medicine on people. This is an early win that shows the medicine might work someday.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.